EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 25-Oct-2026 04:16 ET (25-Oct-2026 08:16 GMT/UTC)

15-Sep-2026

Prostate cancer: Specialized imaging could prevent unnecessary biopsies

Medical University of Vienna
Peer-Reviewed Publication

An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis. Where there is a corresponding suspicion, a tissue sample is therefore usually taken from the prostate. A study by the Medical University of Vienna now shows that a specialised form of imaging – known as PSMA-PET/CT – could provide important additional information even before such a biopsy is carried out. In an analysis of 194 patients, the method detected 91 per cent of clinically relevant prostate cancers. The findings of the research team, led by Marcus Hacker, Head of the Division of Nuclear Medicine at the Department of Biomedical Imaging and Image-guided Therapy, were published in the inaugural issue of the new journal The Lancet Medical Imaging & Theranostics.

14-Sep-2026

Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC

International Association for the Study of Lung Cancer
Reports and Proceedings

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

Study identifies distinct outcomes and genomic features in NSCLC with class II and III BRAF alterations

International Association for the Study of Lung Cancer
Reports and Proceedings

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC

International Association for the Study of Lung Cancer
Reports and Proceedings

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

These results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea.

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

IASLC tumor budding grade identifies high-risk patients with resected lung squamous cell carcinoma

International Association for the Study of Lung Cancer
Reports and Proceedings

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer (WCLC).

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases

International Association for the Study of Lung Cancer
Reports and Proceedings

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

Mobile CT lung cancer screening expands access for underserved populations in Brazil

International Association for the Study of Lung Cancer
Reports and Proceedings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Meeting: The International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer

14-Sep-2026

Fecal microbiota transplantation may improve immunotherapy-related colitis

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

Targeting the gut microbiome with fecal microbiota transplantation (FMT) may help cancer patients with immunotherapy-related colitis avoid the need for steroids and other immune-suppressing treatments, according to researchers at The University of Texas MD Anderson Cancer Center.

Journal: Cell Reports Medicine

14-Sep-2026

Georgetown investigator presents final PAPILLON trial results showing long-term survival in a subset of lung cancer

Georgetown University Medical Center
Reports and Proceedings

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

14-Sep-2026

Brain MRI surveillance without prophylactic cranial irradiation improves cognitive outcomes in small cell lung cancer

SWOG Cancer Research Network
Reports and Proceedings

Small-cell lung cancer (SCLC) often spreads to the brain, and prophylactic cranial irradiation (PCI) has long been prescribed to counter this. But brain irradiation takes a neurocognitive toll. New results of phase 3 SWOG S1827 show regular MRI surveillance alone – versus MRI + PCI – improved cognitive outcomes for these patients without compromising survival.